A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

What is the purpose of this trial?

The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab in combination with ipilimumab in treating patients/subjects with advanced renal cell carcinoma.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Bristol-Myers Squibb Research and Development

Start Date: 08/28/2017

End Date: 02/01/2020

Last Updated: 03/15/2018

Study HIC#: 2000020529

Get Involved

For more information about this study, contact:
Neta Shanwetter Levit
+1 203-737-6247
neta.shanwetterlevit@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Harriet Kluger

Principal Investigator

Sub-Investigators